Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (381-390 of 427) with videos related to

Pageof 43
Sort By:
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Blood Advances|February 24, 2026
Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiomeLilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Pageof 43

Showing results (381-390 of 427) with videos related to

Sort By:
Pageof 43
Blood|May 10, 2024
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myelomaAnthony M Cirrincione, Alexandra M Poos, Bachisio Ziccheddu, et al.
BMC Cancer|April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaMarc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Blood Advances|February 24, 2026
Fiber intake associates with increased treatment response in multiple myeloma patients along changes in gut microbiomeLilli Sophie Sester, Iuliia Galeeva, Juliana de Castilhos, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple MyelomaMartin F Kaiser, Pieter Sonneveld, David A Cairns, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|July 6, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.
Pageof 43